A Phase IB Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Crovalimab (Primary)
- Indications Sickle cell anaemia; Vaso-occlusive crisis
- Focus Adverse reactions
- Acronyms CROSSWALK-a
- Sponsors Roche
- 16 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 30 Jul 2024 Planned End Date changed from 14 Jul 2025 to 31 Oct 2025.
- 30 Jul 2024 Planned primary completion date changed from 14 Jan 2025 to 31 Mar 2025.